Testing for anti-cyclic citrullinated peptide antibodies: Is it time to set this genie free?

Archives of Internal Medicine

Volumn 169, Issue 1, 2009, Pages 9-14

  Shmerling, Robert H ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ARTHRALGIA; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; HUMAN; NOTE; POLYARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIBODIES, ANTINUCLEAR; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 58349101313     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2008.522     Document Type: Note

References (36)

1. Hoet RM, Boerbooms AM, Arends M, Ruiter DJ, van Venrooij WJ. Antiperinuclear factor, a marker antibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin. Ann Rheum Dis. 1991;50(9):611-618.
2. Wener MH, Hutchinson K, Morishima C, Gretch DR. Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum. 2004;50(7):2305-2308.
3. Palosuo T, Lukka M, Alenius H, et al. Purification of filaggrin from human epidermis and measurement of antifilaggrin autoantibodies in sera from patients with rheumatoid arthritis by an enzyme-linked immunosorbent assay. Int Arch Allergy Immunol. 1998;115(4):294-302.
4. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101(1):273-281.
5. Paimela L, Palosuo T, Aho K, et al. Association of autoantibodies to filaggrin with an active disease in early rheumatoid arthritis. Ann Rheum Dis. 2001;60(1):32-35.
6. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis. 2003;62(9):870-874.
7. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-CCP (cyclic citrullinated protein) antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2006;65(7):845-851.
8. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797-808.
9. Rantapää-Dahlqvist S, de Jong BAW, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741-2749.
10. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors Arthritis Rheum. 2004;50(2):380-386.
11. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526-1533.
12. De Rycke L, Nicholas AP, Cantaert T, et al. Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity. Arthritis Rheum. 2005;52(8):2323-2330.
13. Chang X, Yamada R, Suzuki A, et al. Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatology (Oxford). 2005;44(1):40-50.
14. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38-46.
15. Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij WJ, Tak PP. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum. 2004;50(11):3485-3494.
16. Vander Cruyssen B, Hoffman IE, Zmierczak H, et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis. 2005;64(8):1145-1149.
17. Fabien N, Olsson NO, Goetz J, et al. Prevalence of autoantibodies to cyclic citrullinated peptide in patients with rheumatic diseases other than rheumatoid arthritis: a French multicenter study. Clin Rev Allergy Immunol. 2008;34(1):40-44.
18. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-324.
19. Harrison BJ, Symmons DP, Barrett EM, Silman AJ; American Rheumatism Association. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. J Rheumatol. 1998;25(12):2324-2330.
20. Shmerling RH, Delbanco TL. The rheumatoid factor: an analysis of clinical utility Am J Med. 1991;91(5):528-534.
21. Meyer O, Nicaise-Roland P, dos Santos M, et al. Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Res Ther. 2006;8(2):R40.
22. van Gaalen FA, van Aken J, Huizinga TW, et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum. 2004;50(7):2113-2121.
23. Forslind K, Ahlmén M, Eberhardt K, Hafström I, Svensson B; BARFOT Study Group. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis. 2004;63(9):1090-1095.
24. van Gaalen FA, Visser H, Huizinga TW. A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis. 2005;64(10):1510-1512.
25. Turesson C, Jacobsson LT, Sturfelt G, Matteson EL, Mathsson L, Rönnelid J. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(1):59-64.
26. Edwards JC, Cambridge G. Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford). 2005;44(2):151-156.
27. Khan MA. Update on spondyloarthropathies. Ann Intern Med. 2002;136(12):896-907.
28. Härle P, Bongartz T, Schölmerich J, Müller-Ladner U, Straub RH. Predictive and potentially predictive factors in early arthritis: a multidisciplinary approach. Rheumatology (Oxford). 2005;44(4):426-433.
29. Kerr LD. Inflammatory arthropathy: a review of rheumatoid arthritis in older patients. Geriatrics. 2004;59(10):32-35.
30. Nell VP, Machold KP, Stamm TA, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis. 2005;64(12):1731-1736.
31. van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;56(5):1424-1432.
32. van der Helm-van Mil AH, le Cessie S, van Dongen H, Breedveld FC, Toes RE, Huizinga TW. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis. Arthritis Rheum. 2007;56(2):433-440.
33. Shmerling RH, Delbanco TL. How useful is the rheumatoid factor? an analysis of sensitivity, specificity and predictive value. Arch Intern Med. 1992;152(12):2417-2420.
34. Vassilopoulos D, Calabrese LH. Rheumatic manifestations of hepatitis C infection. Curr Rheumatol Rep. 2003;5(3):200-204.
35. Sterling RK, Bralow S. Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep. 2006;8(1):53-59.
36. Skogh T. Does a positive anti-CCP test identify a distinct arthritis entity? Arthritis Res Ther. 2005;7(6):230-232.